Literature DB >> 22565502

Isoprostanes as physiological mediators of transition to newborn life: novel mechanisms regulating patency of the term and preterm ductus arteriosus.

Jian-Xiong Chen1, Patrick W O'Mara, Stanley D Poole, Naoko Brown, Noah J Ehinger, James C Slaughter, Bibhash C Paria, Judy L Aschner, Jeff Reese.   

Abstract

BACKGROUND: Increased oxygen tension at birth regulates physiologic events that are essential to postnatal survival, but the accompanying oxidative stress may also generate isoprostanes. We hypothesized that isoprostanes regulate ductus arteriosus (DA) function during postnatal vascular transition.
METHODS: Isoprostanes were measured by gas chromatography-mass spectrometry. DA tone was assessed by pressure myography. Gene expression was measured by quantitative PCR.
RESULTS: Oxygen exposure was associated with increased 8-iso-prostaglandin (PG)F2α in newborn mouse lungs. Both 8-iso-PGE2 and 8-iso-PGF2α induced concentration-dependent constriction of the isolated term DA, which was reversed by the thromboxane A2 (TxA2) receptor antagonist SQ29548. SQ29548 pretreatment unmasked an isoprostane-induced DA dilation mediated by the EP4 PG receptor. Exposure of the preterm DA to 8-iso-PGE2 caused unexpected DA relaxation that was reversed by EP4 antagonism. In contrast, exposure to 8-iso-PGF2α caused preterm DA constriction via TxA2 receptor activation. Further investigation revealed the predominance of the TxA2 receptor at term, whereas the EP4 receptor was expressed and functionally active from mid-gestation onward.
CONCLUSION: This study identifies a novel physiological role for isoprostanes during postnatal vascular transition and provide evidence that oxidative stress may act on membrane lipids to produce vasoactive mediators that stimulate physiological DA closure at birth or induce pathological patency of the preterm DA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22565502      PMCID: PMC3586272          DOI: 10.1038/pr.2012.58

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  45 in total

1.  Lipid peroxidation in cord blood and neonatal outcome.

Authors:  Barry Weinberger; Salman Nisar; Mujahid Anwar; Barbara Ostfeld; Thomas Hegyi
Journal:  Pediatr Int       Date:  2006-10       Impact factor: 1.524

2.  Relationship between isoprostane concentrations, metabolic acidosis, and morbid neonatal outcome.

Authors:  Michael Scott Rogers; Chi Chiu Wang; Tze Kin Lau; Xin Xiao; Xiao Guang Zhou; Tai Fai Fok; Kai On Chu; Chi Pui Pang
Journal:  Clin Chem       Date:  2005-07       Impact factor: 8.327

3.  Attenuated cyclooxygenase-2 expression contributes to patent ductus arteriosus in preterm mice.

Authors:  Darshini B Trivedi; Yukihiko Sugimoto; Charles D Loftin
Journal:  Pediatr Res       Date:  2006-10-25       Impact factor: 3.756

Review 4.  Cardiovascular pharmacology and physiology of the isoprostanes.

Authors:  Jean-Luc Cracowski; Thierry Durand
Journal:  Fundam Clin Pharmacol       Date:  2006-10       Impact factor: 2.748

5.  Inhibition of cyclooxygenase isoforms in late- but not midgestation decreases contractility of the ductus arteriosus and prevents postnatal closure in mice.

Authors:  Jeff Reese; Judy D Anderson; Naoko Brown; Christine Roman; Ronald I Clyman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-07-20       Impact factor: 3.619

6.  E-ring 8-isoprostanes are agonists at EP2- and EP4-prostanoid receptors on human airway smooth muscle cells and regulate the release of colony-stimulating factors by activating cAMP-dependent protein kinase.

Authors:  Deborah L Clarke; Maria G Belvisi; Elizabeth Hardaker; Robert Newton; Mark A Giembycz
Journal:  Mol Pharmacol       Date:  2004-11-04       Impact factor: 4.436

7.  Oxygen activates the Rho/Rho-kinase pathway and induces RhoB and ROCK-1 expression in human and rabbit ductus arteriosus by increasing mitochondria-derived reactive oxygen species: a newly recognized mechanism for sustaining ductal constriction.

Authors:  Hidemi Kajimoto; Kyoko Hashimoto; Sandra N Bonnet; Alois Haromy; Gwyneth Harry; Rohit Moudgil; Toshio Nakanishi; Ivan Rebeyka; Bernard Thébaud; Evangelos D Michelakis; Stephen L Archer
Journal:  Circulation       Date:  2007-03-12       Impact factor: 29.690

8.  Plasma esterified F2-isoprostanes and oxidative stress in newborns: role of nonprotein-bound iron.

Authors:  Cinzia Signorini; Serafina Perrone; Cristiana Sgherri; Lucia Ciccoli; Giuseppe Buonocore; Silvia Leoncini; Viviana Rossi; Daniela Vecchio; Mario Comporti
Journal:  Pediatr Res       Date:  2008-03       Impact factor: 3.756

9.  Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress.

Authors:  Ginger L Milne; Huiyong Yin; Joshua D Brooks; Stephanie Sanchez; L Jackson Roberts; Jason D Morrow
Journal:  Methods Enzymol       Date:  2007       Impact factor: 1.600

10.  Biomarkers of oxidative stress and antioxidant status in children born small for gestational age: evidence of lipid peroxidation.

Authors:  Maria C P Franco; Elisa M Kawamoto; Renata Gorjão; Viviani M F Rastelli; Rui Curi; Cristoforo Scavone; Ana Lydia Sawaya; Zuleica Bruno Fortes; Ricardo Sesso
Journal:  Pediatr Res       Date:  2007-08       Impact factor: 3.756

View more
  4 in total

1.  Predictors of successful closure of patent ductus arteriosus with indomethacin.

Authors:  M F Ahamed; P Verma; S Lee; M Vega; D Wang; M Kim; M Fuloria
Journal:  J Perinatol       Date:  2015-04-09       Impact factor: 2.521

Review 2.  The isoprostanes--25 years later.

Authors:  Ginger L Milne; Qi Dai; L Jackson Roberts
Journal:  Biochim Biophys Acta       Date:  2014-10-30

Review 3.  Prenatal effects of maternal consumption of polyphenol-rich foods in late pregnancy upon fetal ductus arteriosus.

Authors:  Paulo Zielinsky; Stefano Busato
Journal:  Birth Defects Res C Embryo Today       Date:  2013-12

Review 4.  Patent ductus arteriosus and oxidative stress in preterm infants: a narrative review.

Authors:  Carlo Dani; Simone Pratesi
Journal:  Transl Pediatr       Date:  2020-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.